Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 188.8.131.52) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition.
Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.
Report Source: www.themarketreports.com/report/cy…e-review-h2-2017
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4
- The report reviews Cyclin Dependent Kinase 4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 4 targeted therapeutics and enlists all their major and minor projects
Report available at: www.themarketreports.com/report/buy-now/941456
- Beta Pharma Inc
- Eli Lilly and Co
- G1 Therapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- MEI Pharma Inc
- Novartis AG
- Onconova Therapeutics Inc
- Pfizer Inc
- Sihuan Pharmaceutical Holdings Group Ltd
- Teijin Pharma Ltd
- Tiziana Life Sciences Plc
- ViroStatics srl
Got a question; ask us at: www.themarketreports.com/report/ask-your-query/941456
Category: Market Research Publishers and RetailersCompany about: The Market Reports aims to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are dealing with so many Publishers, we can actually give you what suits best in accordance to your requirements.
For more information: